Bulpitt C J
Division of Geriatric Medicine, Royal Postgraduate Medical School, London, England.
J Cardiovasc Pharmacol. 1996;27 Suppl 2:S31-5. doi: 10.1097/00005344-199600002-00007.
The randomized trials assessing the effect of angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure (CHF) are reviewed. The Minnesota Living with Heart Failure Questionnaire has demonstrated the benefits of enalapril in some but not all circumstances and the Yale Dyspnea-Fatigue Index improves with lisinopril. A recent trial of both cilazapril and captopril vs. placebo employed the Sickness Impact Profile and supports the concept that ACE inhibitors have a small (and in this trial nonsignificant) beneficial effect on mobility. Other vasodilators and inotropes may also have small benefits on quality of life, such that comparisons of an ACE inhibitor with vasodilators, as was done in the V-HeFT II trial, fail to reveal any different effects on quality of life.
对评估血管紧张素转换酶（ACE）抑制剂在慢性心力衰竭（CHF）中作用的随机试验进行了综述。明尼苏达心力衰竭生活问卷已证明依那普利在某些但并非所有情况下都有益处，而耶鲁呼吸困难-疲劳指数会随着赖诺普利而改善。最近一项比较西拉普利和卡托普利与安慰剂的试验采用了疾病影响量表，并支持ACE抑制剂对活动能力有微小（且在该试验中无显著意义）有益作用这一概念。其他血管扩张剂和正性肌力药物可能对生活质量也有微小益处，以至于在V-HeFT II试验中对ACE抑制剂与血管扩张剂进行比较时，未发现对生活质量有任何不同影响。
